Drug Type Peptide drug conjugates |
Synonyms PDL1-targeting polypeptide-MPA-SN38 conjugate, XM146 01, XM14601 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS Registry86639-52-3 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Preclinical | South Korea | 17 Jun 2024 |





